Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)

SHA:688373 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	252.32	316.1	386.26	166.31	151.09	145.52
Trading Asset Securities	97.79	135.54	207.36	786.98	1,119	326.36
Cash & Short-Term Investments	350.1	451.64	593.62	953.3	1,270	471.88
Cash Growth	-27.62%	-23.92%	-37.73%	-24.95%	169.17%	-25.92%
Accounts Receivable	46.79	37.96	31.88	21.98	11.1	1.42
Other Receivables	20.49	20.52	21.02	0.19	0.34	0
Receivables	67.29	58.47	52.9	22.17	11.44	1.42
Inventory	49.03	50.25	52.94	37.52	21.89	11.01
Other Current Assets	50.26	62.09	49.21	41.27	67.01	25.29
Total Current Assets	516.68	622.46	748.66	1,054	1,371	509.59
Property, Plant & Equipment	53.72	61.73	75.8	86.21	97.46	122.8
Other Intangible Assets	0.54	0.95	1.68	1.93	2.19	0.84
Long-Term Deferred Charges	13.75	16.04	19.1	21.75	22.68	1.83
Other Long-Term Assets	3.91	3.91	3.89	4.42	4.54	13.48
Total Assets	590	705.09	849.13	1,169	1,497	648.54

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	56.23	16.57	26.21	11.13	10.85	1.91
Accrued Expenses	2.76	96.51	78.63	94.51	37.41	29.45
Short-Term Debt	25.06	25.02	5	-	48.75	50.08
Current Portion of Long-Term Debt	113.86	68.42	89.23	14.15	10.1	-
Current Portion of Leases	-	12.77	11.51	10.38	6.47	11.04
Current Income Taxes Payable	15.48	0.2	-	4.41	-	-
Current Unearned Revenue	0.47	0.47	-	0.13	-	-
Other Current Liabilities	22.04	4.42	1.71	1.93	1.52	1.71
Total Current Liabilities	235.92	224.38	212.3	136.65	115.11	94.19
Long-Term Debt	142.16	213.04	122.94	114.96	70	-
Long-Term Leases	59.69	60.38	73.18	81.7	94.89	99.87
Long-Term Unearned Revenue	1.45	1.75	1.75	1.25	3.1	16.1
Total Liabilities	439.21	499.55	410.16	334.56	283.1	210.17

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	656.23	656.23	655.61	655.21	655.21	525.21
Additional Paid-In Capital	1,588	1,588	1,571	1,532	1,495	636.77
Retained Earnings	-2,094	-2,046	-1,805	-1,364	-942.85	-722.55
Comprehensive Income & Other	0.31	7.69	17.08	10.91	7.19	-1.06
Shareholders' Equity	150.79	205.54	438.96	834	1,214	438.37
Total Liabilities & Equity	590	705.09	849.13	1,169	1,497	648.54

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	340.77	379.62	301.86	221.19	230.21	160.99
Net Cash (Debt)	9.33	72.02	291.76	732.11	1,040	310.88
Net Cash Growth	-92.15%	-75.32%	-60.15%	-29.60%	234.52%	-50.69%
Net Cash Per Share	0.01	0.11	0.44	1.12	1.79	0.59
Filing Date Shares Outstanding	796.29	655.61	655.61	655.21	655.21	525.21
Total Common Shares Outstanding	796.29	655.61	655.61	655.21	655.21	525.21
Working Capital	280.77	398.08	536.37	917.61	1,255	415.39
Book Value Per Share	0.19	0.31	0.67	1.27	1.85	0.83
Tangible Book Value	150.24	204.59	437.28	832.07	1,212	437.53
Tangible Book Value Per Share	0.19	0.31	0.67	1.27	1.85	0.83
Machinery	-	14.8	14.41	14.18	11.75	6.01
Construction In Progress	-	-	-	-	-	15.65

Data Source: S&P Global Market Intelligence Last updated: Oct 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 9, 2026

Data Sources Report a data error